JP2018515563A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515563A5 JP2018515563A5 JP2017560573A JP2017560573A JP2018515563A5 JP 2018515563 A5 JP2018515563 A5 JP 2018515563A5 JP 2017560573 A JP2017560573 A JP 2017560573A JP 2017560573 A JP2017560573 A JP 2017560573A JP 2018515563 A5 JP2018515563 A5 JP 2018515563A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- alkenyl
- aryl
- nhco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102000001332 SRC Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108010087686 src-Family Kinases Proteins 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1508747.1 | 2015-05-21 | ||
| GBGB1508747.1A GB201508747D0 (en) | 2015-05-21 | 2015-05-21 | Compounds |
| PCT/GB2016/051057 WO2016185160A1 (en) | 2015-05-21 | 2016-04-15 | Compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515563A JP2018515563A (ja) | 2018-06-14 |
| JP2018515563A5 true JP2018515563A5 (enExample) | 2019-03-14 |
| JP6684831B2 JP6684831B2 (ja) | 2020-04-22 |
Family
ID=53506149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560573A Active JP6684831B2 (ja) | 2015-05-21 | 2016-04-15 | 化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10294227B2 (enExample) |
| EP (1) | EP3298015B1 (enExample) |
| JP (1) | JP6684831B2 (enExample) |
| CN (1) | CN107849050B (enExample) |
| CA (1) | CA3021550C (enExample) |
| ES (1) | ES2780382T3 (enExample) |
| GB (1) | GB201508747D0 (enExample) |
| WO (1) | WO2016185160A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190366331A1 (en) * | 2016-12-15 | 2019-12-05 | Tunghai University | Assay plate and manufacturing method thereof |
| HUE068023T2 (hu) | 2017-04-18 | 2024-12-28 | Lilly Co Eli | Fenil-2-hidroxi-acetilamino-2-metil-fenil vegyületek |
| WO2020010204A1 (en) * | 2018-07-05 | 2020-01-09 | Icahn School Of Medicine At Mount Sinai | Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use |
| EP3753944A1 (en) * | 2019-06-17 | 2020-12-23 | Institute Of Biotechnology Cas, V.V.I. | 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments |
| AU2020336975A1 (en) * | 2019-08-29 | 2022-03-31 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds |
| AU2020340427A1 (en) | 2019-08-29 | 2022-03-31 | Hibercell, Inc. | PERK inhibiting compounds |
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| WO2023017264A1 (en) | 2021-08-11 | 2023-02-16 | The University Court Of The University Of Edinburgh | Tyrosine kinase inhibitors |
| JP2024544558A (ja) * | 2021-11-15 | 2024-12-03 | ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド | Ｓｒｃ阻害剤としての化合物 |
| US20250241916A1 (en) | 2022-04-07 | 2025-07-31 | Nuvectis Pharma, Inc. | Tyrosine kinase inhibitors |
| WO2025101861A1 (en) * | 2023-11-08 | 2025-05-15 | Nuvectis Pharma, Inc. | Crystalline forms of the tyrosine kinase inhibitor ecf506 |
| WO2025101874A1 (en) * | 2023-11-08 | 2025-05-15 | Nuvectis Pharma, Inc. | Crystalline salt forms of the tyrosine kinase inhibitor ecf506 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| EP2528919B1 (en) | 2010-01-28 | 2016-11-02 | University of Washington | Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases |
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| CN104379586B (zh) | 2012-05-31 | 2018-01-16 | 制药科学公司 | 蛋白激酶抑制剂 |
| WO2015018333A1 (en) | 2013-08-06 | 2015-02-12 | Fujian Haixi Pharmaceuticals Co., Ltd | Inhibitors of bruton's tyrosine kinase |
-
2015
- 2015-05-21 GB GBGB1508747.1A patent/GB201508747D0/en not_active Ceased
-
2016
- 2016-04-15 JP JP2017560573A patent/JP6684831B2/ja active Active
- 2016-04-15 CA CA3021550A patent/CA3021550C/en active Active
- 2016-04-15 US US15/576,101 patent/US10294227B2/en active Active
- 2016-04-15 CN CN201680042794.5A patent/CN107849050B/zh active Active
- 2016-04-15 WO PCT/GB2016/051057 patent/WO2016185160A1/en not_active Ceased
- 2016-04-15 EP EP16717993.6A patent/EP3298015B1/en active Active
- 2016-04-15 ES ES16717993T patent/ES2780382T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515563A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| JP2017525753A5 (enExample) | ||
| JP2014503525A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| JP2020537657A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| JP2019519598A5 (enExample) | ||
| JP2016529324A5 (enExample) | ||
| JP2016507575A5 (enExample) | ||
| JP2017535614A5 (enExample) | ||
| JP2020503010A5 (enExample) | ||
| JP2016512531A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2013544846A5 (enExample) | ||
| JP2018529650A5 (enExample) | ||
| JP2016513130A5 (enExample) | ||
| JP2012515776A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| JP2019510810A5 (enExample) | ||
| JP2013533879A5 (enExample) | ||
| JP2015516429A5 (enExample) | ||
| HK1211289A1 (en) | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| JP2016506962A5 (enExample) |